Federico Gardini
Corporate Officer/Principal chez Bio3 Research SRL
Postes actifs de Federico Gardini
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - | - |
Historique de carrière de Federico Gardini
Anciens postes connus de Federico Gardini
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bio3 Research, Inc. | Directeur des opérations | - | - |
Formation de Federico Gardini
University of Bocconi | Undergraduate Degree |
Statistiques
Internationale
Italie | 3 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chief Operating Officer | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Health Technology |
Bio3 Research, Inc. |
- Bourse
- Insiders
- Federico Gardini
- Expérience